Proxy Votes Now

Home › Funds › T. Rowe Price › Health Care ETF

Health Care ETF (TMED) proxy voting record 2025-2026

Fund family: T. Rowe Price · Filed by T. Rowe Price Exchange-Traded Funds, Inc. (CIK 1795351) · SEC series S000092023

Ticker: TMED (C000259933)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 812 with, 12 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 2 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with T. Rowe Price as a whole

The same two figures as T. Rowe Price’s manager page (244,024 ballot items across 112 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsT. Rowe PriceItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.5%77093.7%208,710
Backed environmental and social shareholder proposals at US companiesn/a32.6%3,333

Where this fund voted differently from most T. Rowe Price funds

Each ballot item this fund voted is set against the votes of the other T. Rowe Price funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most T. Rowe Price funds on 30 items (4.1% of the 733 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost T. Rowe Price fundsMgmtResult
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Christine A. PoonAgainstFOR — 25 of 25 T. Rowe Price fundsAgainstElected, 76.8% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Craig B. Thompson, M.D.AgainstFOR — 25 of 25 T. Rowe Price fundsAgainstElected, 79.3% support
Stryker Corporation2026-05-06Election Directors: Emmanuel P. MacedaAgainstFOR — 28 of 30 T. Rowe Price fundsAgainstElected, 81.9% support
Thermo Fisher Scientific Inc.2026-05-20An advisory vote to approve named executive officer compensation.AgainstFOR — 36 of 41 T. Rowe Price fundsAgainstNot approved, 31.8% support
Natera, Inc.2026-06-11To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notiForWITHHOLD — 27 of 30 T. Rowe Price fundsForPassed (calculated), 87.1% support
Natera, Inc.2026-06-11To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notiForWITHHOLD — 27 of 30 T. Rowe Price fundsForPassed (calculated), 84.7% support
Natera, Inc.2026-06-11To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notiForWITHHOLD — 27 of 30 T. Rowe Price fundsForPassed (calculated), 87.1% support
Natera, Inc.2026-06-11To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notiWithholdFOR — 27 of 30 T. Rowe Price fundsAgainstPassed (calculated), 98.3% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Joseph L. Goldstein, M.D.AgainstFOR — 22 of 25 T. Rowe Price fundsAgainstElected, 70.1% support
Eli Lilly and Company2026-05-04Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair.ForAGAINST — 33 of 40 T. Rowe Price fundsAgainstNot approved, 33.7% support
Bruker Corporation2026-05-21Election of four Class II directors to serve for a three-year term expiring in 2028: John J. (Jack) PhillipsWithholdFOR — 5 of 5 T. Rowe Price fundsAgainstElected, 98.6% support
Stoke Therapeutics, Inc.2026-06-032 wordings Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: G. Clare Kahn, Ph.D.WithholdFOR — 8 of 9 T. Rowe Price fundsAgainstPassed (calculated), 99.4% support
Stoke Therapeutics, Inc.2026-06-03To approve, on an advisory basis, the compensation of the Company's named executive officers.AgainstFOR — 10 of 12 T. Rowe Price fundsAgainstPassed (calculated), 72.9% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Ian ClarkWithholdFOR — 16 of 22 T. Rowe Price fundsAgainstElected, 65.0% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Manuel Hidalgo MedinaWithholdFOR — 16 of 22 T. Rowe Price fundsAgainstElected, 75.5% support
Biogen Inc.2026-06-093 wordings Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. LangerForAGAINST — 10 of 14 T. Rowe Price fundsForPassed (calculated), 85.3% support
Agios Pharmaceuticals, Inc.2026-06-18To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia SmithWithholdFOR — 5 of 6 T. Rowe Price fundsAgainstPassed (calculated), 68.3% support
Agios Pharmaceuticals, Inc.2026-06-18To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D.WithholdFOR — 5 of 6 T. Rowe Price fundsAgainstPassed (calculated), 87.1% support
Caris Life Sciences, Inc.2026-06-04Election of Directors: Peter M. CastlemanWithholdFOR — 8 of 11 T. Rowe Price fundsAgainstElected, 76.3% support
West Pharmaceutical Services, Inc.2026-05-04Shareholder Shareholder proposal regarding an independent Board Chair policy.ForAGAINST — 9 of 13 T. Rowe Price fundsAgainstNot approved, 46.4% support
Alnylam Pharmaceuticals, Inc.2026-05-20To elect the following nominees as Class I directors of Alnylam: Stuart A. ArbuckleAgainstFOR — 10 of 15 T. Rowe Price fundsAgainstElected, 95.8% support
Ionis Pharmaceuticals, Inc.2026-06-04Election of Directors: Joan E. HermanForAGAINST — 13 of 22 T. Rowe Price fundsForPassed (calculated), 96.4% support
Crinetics Pharmaceuticals, Inc.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Caren DeardorfWithholdFOR — 10 of 16 T. Rowe Price fundsAgainstPassed (calculated), 75.7% support
Crinetics Pharmaceuticals, Inc.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Stephanie S. Okey, M.S.WithholdFOR — 10 of 16 T. Rowe Price fundsAgainstPassed (calculated), 74.5% support
Dianthus Therapeutics, Inc.2026-05-21To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeWithholdFOR — 9 of 16 T. Rowe Price fundsAgainstPassed (calculated), 80.6% support
Show all 30
Items 26 to 30.
CompanyMeetingItemThis fundMost T. Rowe Price fundsMgmtResult
Kodiak Sciences Inc.2026-06-02Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. BancroftWithholdFOR — 8 of 15 T. Rowe Price fundsAgainstElected, 78.7% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: David Schenkein, M.D.WithholdFOR — 8 of 15 T. Rowe Price fundsAgainstElected, 73.5% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: Jennifer CookWithholdFOR — 8 of 15 T. Rowe Price fundsAgainstElected, 60.9% support
Sarepta Therapeutics, Inc.2026-06-04To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Michael ChambersForAGAINST — 3 of 4 T. Rowe Price fundsForElected, 97.4% support
NovoCure Limited2026-06-03The approval of our amended and restated 2024 Omnibus Incentive Plan.ForAGAINST — 2 of 3 T. Rowe Price fundsForApproved, 50.3% support

Download all 30 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 89.1% of this fund’s 824 such votes could be given a sector; the other 90 (10.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care644111.7%
Industrials7300.0%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5200
Audit-related980
Say-on-Pay880
Compensation461
Corporate Governance458
Capital Structure220
Extraordinary Transactions80
Shareholder Rights and Defenses40
Other Social Issues32
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$4M102
UnitedHealth Group IncorporatedJune 1, 2026$2M121
Thermo Fisher Scientific Inc.May 20, 2026$1M130
Humana Inc.April 16, 2026$810,702141
Gilead Sciences, Inc.April 30, 2026$799,524153
Abbott LaboratoriesApril 24, 2026$789,197160
Danaher CorporationMay 5, 2026$623,598140
Waters CorporationMay 21, 2026$446,259130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
April 16, 2026Humana Inc.The stockholder proposal requesting shareholder approval requirement for excessive golden parachutes, if properly presented at the meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 4, 2026West Pharmaceutical Services, Inc.Shareholder proposal regarding an independent Board Chair policy. Shareholder proposalForAgainst
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
April 30, 2026Boston Scientific CorporationStockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposalAgainstFor
May 12, 2026IDEXX Laboratories, Inc.Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposalAgainstFor
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalAgainstFor

Search this fund’s votes by company

835 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Health Care ETF (TMED) voted at 100 shareholder meetings of 97 companies, on 835 ballot items in all. Where management made a recommendation, the fund followed it on 98.5% of the items and voted against it 12 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals less often than T. Rowe Price's funds as a whole (92.5% against 93.7%). It voted differently from most T. Rowe Price funds on 30 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of T. Rowe Price’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.